Innovations for immune disorders
Complement Alternative Pathway is activated in a variety of orphan diseases including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), C3 Glomerulopathy (C3G), Wet and Dry age related macular degenration (AMD), Uveitis, and neuromyelitis optica (NMO) to name a few. Our literature searches revealed that there are in total of more than 100 orphan/non orphan, acute/chronic clinical conditions where complement system is activated. Our intellectual property cover all such diseases. With time, we plan to target the diseases where our clinical candidates would show therapeutic efficacy.
Our laboratory model systems have proven that our clinical candidates effectively prevent formation and deposition of C3b and C5b-9, the two most important complement activation products in disease serum/plasma. Our current therapeutic antibody landscape is pretty unique and is therefore tailored to treat orphan diseases of our time. Our drug candidates do not interfere with the classical pathway.